Fedorak et al., 2004 - Google Patents
Probiotics and the management of inflammatory bowel diseaseFedorak et al., 2004
View PDF- Document ID
- 15663002542011160032
- Author
- Fedorak R
- Madsen K
- Publication year
- Publication venue
- Inflammatory bowel diseases
External Links
Snippet
The demonstration that immune and epithelial cells can discriminate between different microbial species has extended our understanding of the actions of probiotics beyond simple barrier and antimicrobial concepts. Several probiotic mechanisms of action, relative …
- 230000000529 probiotic 0 title abstract description 116
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER, CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using micro-organisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using micro-organisms or enzymes using only micro-organisms of the genus lactobacteriaceae; Yoghurt
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fedorak et al. | Probiotics and the management of inflammatory bowel disease | |
| US12390498B2 (en) | Treatment of clostridium difficile infection | |
| Tamboli et al. | Probiotics in inflammatory bowel disease: a critical review | |
| US11701396B2 (en) | Treatment of Clostridium difficile infection | |
| Hart et al. | Use of probiotics in the treatment of inflammatory bowel disease | |
| Doron et al. | Probiotics: their role in the treatment and prevention of disease | |
| Govender et al. | A review of the advancements in probiotic delivery: Conventional vs. non-conventional formulations for intestinal flora supplementation | |
| KR101982491B1 (en) | Method for preventing and/or treating insulin resistance | |
| CN103037875B (en) | Bifidobacterium strains | |
| ES2437940T3 (en) | Probiotic composition for use in the treatment of inflammation of the intestine | |
| RU2617952C2 (en) | Composition containing n-acetylcysteine in combination with probiotic bacteria able to restore their own stomach barrier effect lost pharma during pharmacological treatment of gastric hyperacidity | |
| Rioux et al. | The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics | |
| Gaon et al. | Effect of lactobacillus strains (L. casei, L. acidophillus strains CERELA) on bacterial overgrowth-related chronic diarrhea | |
| TWI594758B (en) | Composition comprising bifidobacteria,processes for the preparation thereof and uses thereof | |
| JP2009511469A (en) | Probiotics affecting fat metabolism and obesity | |
| JP2002534113A5 (en) | ||
| JP2014505467A (en) | Bifidobacterium CECT7765 and its use in the prevention and / or treatment of overweight, obesity and related lesions | |
| CN103764154A (en) | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes | |
| Fedorak et al. | Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease | |
| WO2009048934A2 (en) | Probiotics for use in relieving symptoms associated with gastrointestinal disorders | |
| Jones et al. | The role of probiotics in inflammatory bowel disease | |
| JP2012180288A (en) | Antibacterial agent | |
| O'May et al. | Health claims associated with probiotics | |
| Vasile et al. | Probiotics-an alternative treatment for various diseases | |
| Ivanovska et al. | Probiotics, prebiotics, synbiotics in prevention and treatment of inflammatory bowel diseases |